四川
分享至
每经AI快讯，先为达生物与辉瑞中国2月24日宣布，双方就新一代偏向型GLP-1受体激动剂埃诺格鲁肽注射液达成商业化战略合作协议。
特别声明：以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布，本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.
